CN120152974A - 缩环哒嗪衍生物 - Google Patents
缩环哒嗪衍生物 Download PDFInfo
- Publication number
- CN120152974A CN120152974A CN202380075583.1A CN202380075583A CN120152974A CN 120152974 A CN120152974 A CN 120152974A CN 202380075583 A CN202380075583 A CN 202380075583A CN 120152974 A CN120152974 A CN 120152974A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- methyl
- salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022-171096 | 2022-10-26 | ||
| JP2022171096 | 2022-10-26 | ||
| PCT/JP2023/038490 WO2024090469A1 (ja) | 2022-10-26 | 2023-10-25 | 縮環ピリダジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120152974A true CN120152974A (zh) | 2025-06-13 |
Family
ID=90830917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380075583.1A Pending CN120152974A (zh) | 2022-10-26 | 2023-10-25 | 缩环哒嗪衍生物 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4610258A1 (https=) |
| JP (1) | JPWO2024090469A1 (https=) |
| CN (1) | CN120152974A (https=) |
| TW (1) | TW202432551A (https=) |
| WO (1) | WO2024090469A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| TW202313577A (zh) | 2021-06-04 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| WO2024251073A1 (zh) * | 2023-06-03 | 2024-12-12 | 成都赜灵生物医药科技有限公司 | 并哒嗪类化合物及其用途 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025180453A1 (zh) * | 2024-02-28 | 2025-09-04 | 纽欧申医药(上海)有限公司 | 哒嗪环衍生物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2940611T3 (es) | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| US11465992B2 (en) | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| WO2019028440A1 (en) * | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| JP2022525417A (ja) | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| CN115279739B (zh) | 2020-03-27 | 2025-07-22 | 尼科治疗有限公司 | 取代哒嗪化合物 |
| WO2022060943A1 (en) | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
| WO2022060951A1 (en) | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
| WO2022135567A1 (zh) | 2020-12-25 | 2022-06-30 | 上海拓界生物医药科技有限公司 | 一类含哒嗪的化合物及其医药用途 |
| EP4289823A4 (en) * | 2021-02-08 | 2025-02-26 | Medshine Discovery Inc. | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES |
| US11319319B1 (en) * | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
-
2023
- 2023-10-25 JP JP2024553099A patent/JPWO2024090469A1/ja active Pending
- 2023-10-25 CN CN202380075583.1A patent/CN120152974A/zh active Pending
- 2023-10-25 EP EP23882674.7A patent/EP4610258A1/en active Pending
- 2023-10-25 WO PCT/JP2023/038490 patent/WO2024090469A1/ja not_active Ceased
- 2023-10-25 TW TW112140824A patent/TW202432551A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2024090469A1 (https=) | 2024-05-02 |
| TW202432551A (zh) | 2024-08-16 |
| EP4610258A1 (en) | 2025-09-03 |
| WO2024090469A1 (ja) | 2024-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6667573B2 (ja) | 新規なアミノピリミジン誘導体 | |
| CN120152974A (zh) | 缩环哒嗪衍生物 | |
| CN115279739B (zh) | 取代哒嗪化合物 | |
| US12473272B2 (en) | JAK1 selective inhibitors | |
| CN117222626A (zh) | 取代三嗪化合物 | |
| US20250084092A1 (en) | Annulated pyridazine compound | |
| WO2021132422A1 (ja) | ピリダジニルチアアゾールカルボキシアミド化合物 | |
| CN105461699B (zh) | 取代的杂环化合物及其使用方法和用途 | |
| JP6689856B2 (ja) | ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用 | |
| EP3174880B1 (en) | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors | |
| CN106349228B (zh) | 取代的喹唑啉酮类化合物及其制备方法和用途 | |
| JP7813290B2 (ja) | Ｔｙｋ２阻害剤 | |
| JP6656246B2 (ja) | プロキネチシン介在消化器疾患を治療するためのスルホニルピペリジン誘導体及びその使用 | |
| HK40127042A (en) | Novel amino pyrimidine derivatives | |
| HK40089302B (en) | Method of preparing amino pyrimidine derivatives | |
| JP2016522244A (ja) | プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体 | |
| HK40024076A (en) | Novel amino pyrimidine derivatives | |
| HK40024076B (en) | Novel amino pyrimidine derivatives | |
| HK1252317B (en) | Novel amino pyrimidine derivatives | |
| HK1223368B (en) | Novel amino pyrimidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |